Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + apatinib + stereotactic body radiotherapy
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
adebrelimab + apatinib + stereotactic body radiotherapy is a combination therapeutic regimen being investigated for the treatment of hepatocellular carcinoma (HCC). The regimen consists of **adebrelimab** (also referred to as adbelimumab or SHR-1316), a humanized IgG4 monoclonal antibody that inhibits the Programmed cell death 1 ligand 1 (PD-L1); **apatinib** (YN968D1), a small molecule tyrosine kinase inhibitor that selectively targets Vascular endothelial growth factor receptor 2 (VEGFR2); and **stereotactic body radiotherapy** (SBRT). This combination is designed to leverage the synergistic effects of immune checkpoint inhibition, anti-angiogenesis, and localized radiation-induced immunogenic cell death. It is currently being evaluated in a Phase II investigator-initiated trial at Fujian Cancer Hospital as a perioperative and conversion therapy to improve surgical resectability and patient outcomes in HCC patients.
- Brand names
- Adely
- Other names
- adbelimumabadebrelimabapatinibrivoceranibSHR-1316SHR1316SHR 1316apatinib mesylateSBRTstereotactic body radiotherapy
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on adebrelimab + apatinib + stereotactic body radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + apatinib + stereotactic body radiotherapy.